Background: Medication diversion represents the largest source of misused opioid analgesics (1) . Unused opioid analgesics are seldom safely stored or disposed of (1-3), creating a large supply for diversion. Most patients lack knowledge about safe storage and disposal of opioids (4) . Recent reports call for clear and consistent messages about safe practices (5) . Providers rarely counsel patients on safe storage and disposal despite promising evidence supporting such interventions as an effective mechanism to improve patient behaviors (4) . Drug package inserts include prescribing information for providers (6) and are an avenue for conveying information on safe storage and disposal. How medication packaging presents this information to providers is unknown.
Objective: To characterize messages on storage and disposal in package inserts for opioid analgesics and describe differences in these messages by opioid type.
Methods and Findings: We selected 6 commonly prescribed and misused types of opioid analgesics: hydrocodone, hydromorphone, tramadol, fentanyl, morphine, and oxycodone (7) . In September 2016, we used DailyMed, an online public resource of labeling information on drug products, to identify the number of products from each type (8). We then extracted package insert information from a 10% random sample of these products. One investigator (M.L.D.) read the sampled package inserts, identified safe storage and disposal messages/phrases, and coded whether each package insert had such messages. The investigators (M.L.D., S.F., and W.C.S.) conferred on messages before coding.
Of an initial sample of 108 inserts, we excluded 10 that pertained to products labeled for hospital use because we considered them at lower risk for diversion. Among the 98 reviewed package inserts, we identified 1 message on safe storage and 3 on safe disposal (Table) . The message on safe storage stated that medications should be securely stored to prevent theft. Approximately two thirds of the 35 package inserts with this message were for oxycodone (n = 16) or morphine (n = 8) products. Messages on safe disposal stated that unused medications should be discarded (n = 31) or flushed down the toilet (n = 34) or that providers should instruct patients to dispose of unused opioids (n = 28). Most (70% to 80%) inserts with messages on safe disposal were for oxycodone and morphine products. None of the inserts for tramadol products had messages on either storage or disposal; 1 of 33 inserts for hydrocodone products had a message on storage or disposal.
Discussion: Providers educating patients on safe storage and disposal practices may reduce the supply of misused prescription opioids. Although we found promising information on safe storage and disposal in package inserts, the messaging was inconsistent across pain reliever types and infrequent or absent for some products. This finding was disappointing, because consistent and explicit messaging is an important component of effective education.
Providers are uniquely positioned to promote safe storage and disposal behaviors in patients, and appropriate edu-cation may decrease medication diversion and unintentional poisonings (4) . Targeting providers with this information through package inserts may improve their counseling of patients about safe practices. Policymakers may consider mandating that information on safe storage and disposal be included in package inserts for opioid analgesics through rulemaking by the U.S. Food and Drug Administration or legislation.
This study is limited by its small sample size and reliance on prescription insert information available in the DailyMed database. It does not take into account other information sources available to providers about drug safety and disposal. Despite these limitations, we believe that increasing the consistency and frequency of information on safe storage and disposal in package inserts may reduce diversion of opioid analgesics and should be explored further by researchers and policymakers. (1) conducted a costeffectiveness analysis (CEA) comparing lung cancer screening using risk-based criteria versus criteria based on NLST (National Lung Screening Trial) enrollment. They concluded, "Our analysis suggests that the gains from such risk-based eligibility likely would be small," implying approximate equivalence between these criteria. A critical limitation of their analysis is that their sample was limited to NLST participants and does not represent the general population of smokers. Of note, they did not evaluate smokers who met risk-based but not NLST criteria. Consider using NLST criteria and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCO M2012 ) 6-year risk for cancer of 1.5% or greater (2, 
